Theratechnologies Inc. has completed an acquisition by Future Pak, with shareholders receiving $3.01 per share in cash and a contingent value right (CVR) with potential additional payments of up to $1.19 per share if certain milestones are achieved.

Theratechnologies Inc. has received final court approval for a plan of arrangement to be acquired by Future Pak, with the transaction expected to close around September 25, 2025.

Theratechnologies shareholders voted 97.44% in favor of a proposed arrangement to be acquired by Future Pak, with the final court order expected on September 16, 2025.

Theratechnologies announced it will report Q2 2025 financial results on July 9, 2025, and will not hold a conference call due to a recent acquisition agreement by CB Biotechnology.

Theratechnologies received unsolicited acquisition proposals from Future Pak, but is in exclusive discussions with another potential acquirer. The company's board has formed a special committee to review the proposals and determine the best course of action for the company and its stakeholders.